Navigation Links
Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
Date:12/1/2008

Company Also Names Christopher Horvath, D.V.M., as Vice President of Preclinical Sciences and Marie Green, Ph.D., as Senior Program Executive

CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -- Taligen Therapeutics Inc. today expanded its Cambridge, Mass.-based executive team with the appointment of Jeffrey T. Walsh as chief business officer. The company also announced the additions of Christopher Horvath, D.V.M., as vice president of preclinical sciences and Marie Green, Ph.D., as senior program executive.

The executive appointments reflect the advancement of Taligen's corporate growth plan, which Taligen initiated in August with the hiring of Abbie Celniker, Ph.D., as chief executive officer. Taligen is focused on building its preclinical, CMC and clinical development operations in Cambridge while maintaining early research activities in the laboratory of Michael Holers, M.D., in Denver.

"I am pleased that Taligen has been able to attract the level of talent and experience that Mr. Walsh, Dr. Horvath and Dr. Green bring to the company," said Celniker. "We now have in place most of the key executives we believe are necessary to advance our lead clinical candidates through preclinical development to IND submission and to continue to advance Taligen's growth plan."

Walsh, will contribute to the development of the company's overall business strategy and oversee finance, legal, business development and general business operations. He has spent more than 20 years in leadership roles in the pharmaceutical and biotechnology industries with a focus on corporate finance, strategic planning and business development while at Inotek Pharmaceuticals Corp., Exact Sciences Corp., Pathogenesis Corp. (now part of Novartis), and SmithKline Beecham (now part of GlaxoSmithKline).

"I am looking forward to working with Dr. Celniker and the rest of the team that she has assembled as we
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
3. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
4. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
5. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
6. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
7. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
8. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
9. Cornerstone Therapeutics Announces New Board of Directors
10. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...alth care reform details emerge, more entrepreneur...roups and business insurance premiums. Now, they a...s such as the Small Business Health Insurance Netw...Minneapolis, Minn. (PRWEB) July 3, 2009 -- The hea...ouse, which has entrepreneurs worried about how th...
(Date:7/2/2009)...o Support Principles to Govern Health Insurer Beha...-USNewswire/ -- Nearly nine out of ten voters (88%... much influence over how doctors care for their pa...he concept of a "Health Insurer Code of Conduct" t...or health insurance companies with respect to how ...
(Date:7/2/2009)...swire-USNewswire/ -- Acetaminophen is an ingredien...medicines to help relieve pain and reduce fever. ..., Tylenol and prescription brand names, Vicodin an...FDA met on June 30, 2009 to address liver related ...mittee voted 20-17 to urge the FDA to put a ban on...
(Date:7/2/2009)...Newswire/ -- Dr Daniel Goldberg, a leading New Jer... measure the effectiveness of using 5% Betadine ir...orldwide, highly contagious and often severe form ... visual impairment due to corneal involvement. , ...to register to participate in the Betadine for EKC...
Breaking Medicine News(10 mins):Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2
...ry measure and action against smoking in Scotland,.... Only adults// would be permitted to buy it. Min...endation, but they are likely to do so, given Jack... reduce smoking rates in Scotland. In the words o...
...e caused by AIDS, it was imperative that a giganti...linton Global Initiative teamed up to bring togeth...activists.The idea behind this exercise was to fin...ler. To involve the people CNN.com asked readers ...
...lic Health Service for Wales published, figures fo...y bugs, including MRSA. This step is taken to assu...ken by the health officials to protect the public....uired MRSA infection after a hip replacement opera...
...esearchers from the Mayo Clinic in Rochester, MN h...utaneous cryoablation //can be of significance in ...d is especially useful in patients who are not con...or the study, researchers treated 59 kidney tumors...
Other Medicine News:Health News:AIDS: from the heart stories about AIDS and you! 2Health News:AIDS: from the heart stories about AIDS and you! 3Health News:New Technique Destroys Kidney Tumors By Freezing Them 2
(Date:6/29/2009)...d, June 29 Vantia Therapeutics, an..., small molecule drugs,targeting large, underserv...m,a Phase IIa clinical trial of its lead developm...wed that oral VA106483 was successful in producing... in patients, as determined by,increased osmolali...
(Date:6/28/2009)... and TOKYO, June 29 , - Stu..., Sosei Group Corporation ("Sosei"; TSE Mothe... LSE: VEC) announce the commencement of a Phase II...-daily, long-acting muscarinic,antagonist (LAMA) ... disease,(COPD). NVA237 is a dry powder formulati...
(Date:6/26/2009)..., "Agendia,s Breast Cancer Recurrence Test MammaPr...onsensus Recommendations" issued,on 23 Jun 2009 1... be advised,that the subheadline was missing from...swire. Complete, corrected release follows: ,...Cancer Recurrence Test MammaPrint Included in,Int...
(Date:6/25/2009)...ical Experts Slated to Attend First National Sympo... -- The first national symposium designed to explo...d next week in New York City when thirteen top exp...their respective fields. The SUNY Youth Sports In...e health impacts that the $5 billion-a-year energy...
Breaking Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4/C O R R E C T I O N -- Agendia B.V./ 2/C O R R E C T I O N -- Agendia B.V./ 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4Shareholder Class Action Filed Against Sequenom Inc by the Law Firm of Barroway Topaz Kessler Meltzer 26 Check LLP 45245 1Shareholder Class Action Filed Against Sequenom Inc by the Law Firm of Barroway Topaz Kessler Meltzer 26 Check LLP 45245 2Shareholder Class Action Filed Against Sequenom Inc by the Law Firm of Barroway Topaz Kessler Meltzer 26 Check LLP 45245 3Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center 45243 1Blue Cross and Blue Shield Funds Diabetes Education at Saints Mary and Elizabeth Medical Center 45243 2APHA Applauds Climate Change Bill That Will Help Protect Public Health 45240 1U S Maternal Health Program 3A Marks 20 Years of Support to Mothers and Childbearing Women 45237 1U S Maternal Health Program 3A Marks 20 Years of Support to Mothers and Childbearing Women 45237 2
...ine out of 10 non-diabetic patients treated with,E...] , Additional average decrease of 20 mmHg in,sys...xforge over,reductions seen with previous monother...sure not,at treatment target levels[2] and most re... , , BASEL, Switzerland, May 21, 2007 - Exforg...
...XED DOSE COMBINATION WITH DIURETIC ACCEPTED FOR RE... NJ, 21 May 2007 -,Speedel (SWX: SPPN) today welc...als of SPP100 (aliskiren, Tekturna/Rasliez[1]),pre...fic Meeting,and Exposition of the American Society...results confirm the favourable safety and,efficacy...
Other Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide l...pment. ARUP offers an extensive test menu of highl... anatomic pathology. Owned by the University of Ut...alf of the nation's university teaching hospitals ...
Medicine Products: